skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an interview at Biotech Showcase. Second Genome has a proprietary microbiome discovery platform that it is using to develop small molecules, peptide biologics and bacterial strains, with one clinical-stage candidate in the pipeline. The company is working with major pharma partners such as Pfizer Venture Fund and Roche Venture Fund, which were among the investors in a Series B round in Spring 2016 and the company is also looking for new partners to develop microbiome candidates in a broad range of diseases, including gastrointestinal conditions, cancer and the metabolic space.



Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: